Abstract
Antibodies to interleukin-2 (IL-2) have been reported in the sera of patients under therapies involving this cytokine and in the sera of patients infected with human immunodeficiency virus (HIV). Our study proves that auto-antibodies to IL-2 are present also, at a lower titre, in healthy individuals. These antibodies were affinity purified and studied for their capability to interfere with the in vitro biological activity of IL-2. Data obtained show that human anti-IL-2 antibodies can interfere with lymphocyte proliferation both in the lymphokine activated killer (LAK) cell assay and in the mixed lymphocyte reaction (MLR). However, the kinetics of inhibition by anti-IL-2 antibodies differs from LAK cell assay to MLR as the former are always inhibited in a time-independent manner, and the latter only by adding antibodies at the outset of culture. The neutralizing activity observed in vitro suggests that such antibodies play a part in the elaborate cytokine network by which the immune system regulates the amplitude and duration of its response.
| Original language | English |
|---|---|
| Pages (from-to) | 472-476 |
| Number of pages | 5 |
| Journal | Scandinavian Journal of Immunology |
| Volume | 38 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
The detection and biological activity of human antibodies to IL-2 in normal donors. / Tiberio, L.; Caruso, A.; Pozzi, A.; Rivoltini, L.; Morelli, D.; Monti, E.; Balsari, A.
In: Scandinavian Journal of Immunology, Vol. 38, No. 5, 1993, p. 472-476.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The detection and biological activity of human antibodies to IL-2 in normal donors
AU - Tiberio, L.
AU - Caruso, A.
AU - Pozzi, A.
AU - Rivoltini, L.
AU - Morelli, D.
AU - Monti, E.
AU - Balsari, A.
PY - 1993
Y1 - 1993
N2 - Antibodies to interleukin-2 (IL-2) have been reported in the sera of patients under therapies involving this cytokine and in the sera of patients infected with human immunodeficiency virus (HIV). Our study proves that auto-antibodies to IL-2 are present also, at a lower titre, in healthy individuals. These antibodies were affinity purified and studied for their capability to interfere with the in vitro biological activity of IL-2. Data obtained show that human anti-IL-2 antibodies can interfere with lymphocyte proliferation both in the lymphokine activated killer (LAK) cell assay and in the mixed lymphocyte reaction (MLR). However, the kinetics of inhibition by anti-IL-2 antibodies differs from LAK cell assay to MLR as the former are always inhibited in a time-independent manner, and the latter only by adding antibodies at the outset of culture. The neutralizing activity observed in vitro suggests that such antibodies play a part in the elaborate cytokine network by which the immune system regulates the amplitude and duration of its response.
AB - Antibodies to interleukin-2 (IL-2) have been reported in the sera of patients under therapies involving this cytokine and in the sera of patients infected with human immunodeficiency virus (HIV). Our study proves that auto-antibodies to IL-2 are present also, at a lower titre, in healthy individuals. These antibodies were affinity purified and studied for their capability to interfere with the in vitro biological activity of IL-2. Data obtained show that human anti-IL-2 antibodies can interfere with lymphocyte proliferation both in the lymphokine activated killer (LAK) cell assay and in the mixed lymphocyte reaction (MLR). However, the kinetics of inhibition by anti-IL-2 antibodies differs from LAK cell assay to MLR as the former are always inhibited in a time-independent manner, and the latter only by adding antibodies at the outset of culture. The neutralizing activity observed in vitro suggests that such antibodies play a part in the elaborate cytokine network by which the immune system regulates the amplitude and duration of its response.
UR - http://www.scopus.com/inward/record.url?scp=0027424864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027424864&partnerID=8YFLogxK
U2 - 10.1111/j.1365-3083.1993.tb02590.x
DO - 10.1111/j.1365-3083.1993.tb02590.x
M3 - Article
C2 - 8235450
AN - SCOPUS:0027424864
VL - 38
SP - 472
EP - 476
JO - Scandinavian Journal of Immunology
JF - Scandinavian Journal of Immunology
SN - 0300-9475
IS - 5
ER -